In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Metra Biosystems Inc.

Division of Quidel Corp.

Latest From Metra Biosystems Inc.

A Buyer's Market in Diagnostics

Deal activity in diagnostics has been way down in 1999 and while a few strategically sound deals are getting done, the scale has been very small. With financing and M&A options drying up, smaller diagnostics companies are more squeezed than ever. A plucky few have snared good deals. Here's how.
Medical Device Strategy

The Price of Distress Sales

The small-cap intra-biotech M&A deals now occurring are, at least for sellers, always transactions of last resort--done at extraordinarily dilutive prices. Big Biotech acquisitions, on the other hand, are done for big premiums. In this column, we show the various discounts and premiums biotech acquirers are paying.
BioPharmaceutical Strategy

When the Body Alone Can't Build Bone

Orthobiologics are now on the horizon, driving suppliers to increase R&D spending. The goal is to develop high-margin products that will actively promote bone formation. Has the slow progress to commercialization of the first two products--bone morphogenic proteins developed by the collaborations of Stryker Corp/Creative Biomolecules and Genetics Institute/Sofamor Danek--helped prime the market to accept a new technology? Or has the perception of delay dampened enthusiasm and scared off some of the big orthopedics players?
BioPharmaceutical Medical Device

Can Spectral and Metra Save Each Other?

As young diagnostics companies struggle to survive, perhaps one of the most telling stories is that of Spectral Diagnostics Inc. and Metra Biosystems Inc. Once considered to be among the most promising start-ups of the crop that formed in the late 1980s and early 1990s, both companies have been struggling. Their proposed merger, announced in December, indicates just how ripe the diagnostics industry is for small-cap consolidation.
Medical Device Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Therapeutic Areas
  • Gynecological, Urological
  • Infectious & Viral Diseases
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Quidel Corp.
  • Senior Management
  • Jennifer S Lloyd, VP, Corp. Dev.
    Ronald T Steckel, SVP
    John Coombs, VP, Sales & Mktg.
    Gerald J Allen, PhD, VP, R&D
  • Contact Info
  • Metra Biosystems Inc.
    Phone: (650) 903-9100
    265 North Whisman Rd.
    Mountain View, CA 94043-3911